Targeted Therapies

  • Author: Gail Wilkes, RNC, ANP-BC, MS, AOCN® (More Info)
  • Section Editor: Marlene SanFilippo, MSN, ARNP, FNP-C, AOCNP®
  • Editors In Chief: Dawn Camp-Sorrell, MSN, FNP, AOCN®; Rebecca Hawkins, MSN, ANP, AOCN®, ACHPN
  • Last Reviewed: 7/9/18 (What's New)

Summary

  • Cyclin-dependent kinase inhibitors, abemaciclib (Table 23), palbociclib (Table 24) and ribociclib (Table 25), block cyclin-dependent kinases 4 and 6 that are often disrupted in breast cancer[Cadoo 2014]
  • Unlike other targeted therapy agents, one quarter to one third of patients have alopecia[Finn 2015]

Action required